Latest Safety News

Element 25 Limited advances its global manganese strategy with a $50 million loan for its Butcherbird Mine expansion and a $166 million US Department of Energy grant for a Louisiana battery-grade manganese refinery.

Tasmea Limited forecasts a robust 34% increase in net profit after tax for FY26, driven by a record order book and strategic acquisitions, while reaffirming its FY25 earnings guidance.

Li-S Energy has secured a collaboration and supply agreement with a leading defence technology firm to test its lithium-sulfur batteries for military applications, marking a strategic step into the global defence sector.

Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.

AIC Mines has secured $55 million through a well-supported placement to fund major expansions at its Eloise mine and the development of the Jericho copper project, backed by strategic investor Hawke’s Point.

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.

Collins Foods Limited reported record revenue of $1.52 billion for FY25, up 2.1%, but statutory net profit plunged 88.5% due to significant impairments and wage provisions. The company declared a fully franked final dividend of 15 cents per share, signaling confidence despite challenges.

Amplia Therapeutics has secured US ethics approval to launch a Phase 2 trial combining its drug narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer, marking a key step in its clinical development.

Virgin Australia Holdings Limited is set to list on the ASX, raising $685 million through a mix of new and existing shares, showcasing its transformation journey and strategic partnership with Qatar Airways.

HITIQ Limited has closed its pro-rata rights issue, raising $360,426 before costs, and is now focusing on placing the remaining shortfall of shares within three months.

Ronin Resources Limited updates ASX on delayed exploration activities and relinquished projects, citing socio-political challenges and market conditions. The company anticipates key licence grants by August 2025 and confirms compliance with listing rules while seeking new opportunities.

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.